Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® ...
ORION CORPORATION PRESS RELEASE 21 MAY 2026 at 10:30 EEST Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting First clinical data from the Phase 1/2 TEADES trial of …